Skip to main content
NCBI home page
Wiley - PMC COVID-19 Collection logoLink to Wiley - PMC COVID-19 Collection
. 2007 Dec 13;100(2):273–283. doi: 10.1002/bit.21757

Serum‐free transient protein production system based on adenoviral vector and PER.C6 technology: High yield and preserved bioactivity†

MJE Havenga 1,✉, L Holterman 1, I Melis 1, S Smits 1, J Kaspers 1, E Heemskerk 1, R van der Vlugt 1, M Koldijk 1, GJ Schouten 1, G Hateboer 1, K Brouwer 1, R Vogels 1, J Goudsmit 1
PMCID: PMC7161845  PMID: 18512821

Abstract

Stable E1 transformed cells, like PER.C6, are able to grow at scale and to high cell densities. E1‐deleted adenoviruses replicate to high titer in PER.C6 cells whereas subsequent deletion of E2A from the vector results in absence of replication in PER.C6 cells and drastically lowers the expression of adenovirus proteins in such cells. We therefore considered the use of an ΔE1/ΔE2 type 5 vector (Ad5) to deliver genes to PER.C6 cells growing in suspension with the aim to achieve high protein yield. To evaluate the utility of this system we constructed ΔE1/ΔE2 vector carrying different classes of protein, that is, the gene coding for spike protein derived from the Coronavirus causing severe acute respiratory syndrome (SARS‐CoV), a gene coding for the SARS‐CoV receptor or the genes coding for an antibody shown to bind and neutralize SARS‐CoV (SARS‐AB). The ΔE1/ΔE2A‐vector backbones were rescued on a PER.C6 cell line engineered to constitutively over express the Ad5 E2A protein. Exposure of PER.C6 cells to low amounts (30 vp/cell) of ΔE1/ΔE2 vectors resulted in highly efficient (>80%) transduction of PER.C6 cells growing in suspension. The efficient cell transduction resulted in high protein yield (up to 60 picogram/cell/day) in a 4 day batch production protocol. FACS and ELISA assays demonstrated the biological activity of the transiently produced proteins. We therefore conclude that ΔE1/ΔE2 vectors in combination with the PER.C6 technology may provide a viable answer to the increasing demand for high quality, high yield recombinant protein. Biotechnol. Bioeng. 2008;100: 273–283. © 2007 Wiley Periodicals, Inc.

Keywords: protein production, human PER.C6® cells, recombinant adenovirus, serum‐free medium

†

M.J.E. Havenga and L. Holterman contributed equally to this work.

References

  1. Andersen DC, Krummen L. 2002. Recombinant protein expression for therapeutic applications. Curr Opin Biotechnol 13(2): 117–123. [DOI] [PubMed] [Google Scholar]
  2. Andersson C, Hansson M, Power U, Nygren Pk, Ståhl S. 2001. Mammalian cell production of a respiratory syncytial virus (RSV) candidate vaccine recovered using a product‐specific affinity column. Biotechnol Appl Biochem 34(Pt 1): 25–32. [DOI] [PubMed] [Google Scholar]
  3. Baldi L, Hacker DL, Adam M, Wurm FM. 2007. Recombinant protein production by large‐scale transient gene expression in mammalian cells: state of the art and future perspectives. Biotechnol Lett 29(5): 677–684. [DOI] [PubMed] [Google Scholar]
  4. Bao WG, Fukuhara H. 2001. Secretion of human proteins from yeast: Stimulation by duplication of polyubiquitin and protein disulfide isomerase genes in Kluyveromyces lactis. Gene 272(1–2): 103–110. [DOI] [PubMed] [Google Scholar]
  5. Berg H, Walter M, Mauch L, Seissler J, Northemann W. 1993. Recombinant human preproinsulin. Expression, purification and reaction with insulin autoantibodies in sera from patients with insulin‐dependent diabetes mellitus. J Immunol Methods 164(2): 221–231. [DOI] [PubMed] [Google Scholar]
  6. Boedeker BG. 2001. Production processes of licensed recombinant factor VIII preparations. Semin Thromb Hemost 27(4): 385–394. [DOI] [PubMed] [Google Scholar]
  7. Breitbach K, Jarvis DL. 2001. Improved glycosylation of a foreign protein by Tn‐5B 1‐4cells engineered to express mammalian glycosyltransferases. Biotechnol Bioeng 74(3): 230–239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Brink EN van den, Meulen J ter, Cox F, Jongeneelen MA, Thijsse A, Throsby M, Marissen WE, Rood PM, Bakker AB, Gelderblom HR, Martina BE, Osterhaus ADME, Preiser W, Doerr HW, Kruif J de, Goudsmit J. 2005. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocaspid proteins of severe acute respiratory syndrome coronavirus. J Virol 79(3): 1635–1644. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cai X. 2001. Melanin properties studies of the recombinant of Pseudomonas pseudoalcaligenes containing tyrosinase gene. Wei Sheng Wu Xue Bao 41(6): 699–703. [PubMed] [Google Scholar]
  10. Chen L, Colman PM, Cosgrove LJ, Lawrence MC, Lawrence LJ, Tulloch PA, Gorman JJ. 2001. Cloning, expression, and crystallization of the fusion protein of Newcastle disease virus. Virology 290(2): 290–299. [DOI] [PubMed] [Google Scholar]
  11. Côté J, Garnier A, Massie B, Kamen A. 1998. Serum‐free production of recombinant proteins and adenoviral vectors by 293SF‐3F6 cells. Biotechnol Bioeng 59(5): 567–575. [PubMed] [Google Scholar]
  12. Derouazi M, Girard P, Van Tilborgh F, Iglesias K, Muller N, Bertschinger M, Wurm FM. 2004. Serum‐free large‐scale transient transfection of CHO cells. Biotechnol Bioeng 87(4): 537–545. [DOI] [PubMed] [Google Scholar]
  13. Ensinger MJ, Ginsberg HS. 1972. Selection and preliminary characterization of temperature‐sensitive mutants of type 5 adenovirus. J Virol 10(3): 328–329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fallaux FJ, Kranenburg O, Cramer SJ, Houweling A, Van Ormondt H, Hoeben RC, Van Der Eb AJ. 1996. Characterization of 911: A new helper cell line for the titration and propagation of early region 1‐deleted adenoviral vectors. Hum Gene Ther 7(2): 215–222. [DOI] [PubMed] [Google Scholar]
  15. Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, Valerio D, Hoeben RC. 1998. New helper cells and matched early region 1‐deleted adenovirus vectors prevent generation of replication‐competent adenoviruses. Hum Gene Ther 9(13): 1909–1917. [DOI] [PubMed] [Google Scholar]
  16. Fang B, Wang H, Gordon G, Bellinger DA, Read MS, Brinkhous KM, Woo SL, Eisensmith RC. 1996. Lack of persistence of E1—Recombinant adenoviral vectors containing a temperature‐sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Gene Ther 3(3): 217–222. [PubMed] [Google Scholar]
  17. Friehs K, Reardon KF. 1993. Parameters influencing the productivity of recombinant E. coli cultivations. Adv Biochem Eng Biotechnol 48: 53–77. [DOI] [PubMed] [Google Scholar]
  18. Fussenegger M, Bailey JE, Hauser H, Mueller PP. 1999. Genetic optimization of recombinant glycoprotein production by mammalian cells. Trends Biotechnol 17(1): 35–42. [DOI] [PubMed] [Google Scholar]
  19. Garnier A, Côté J, Nadeau I, Kamen A, Massie B. 1994. Scale‐up of the adenovirus expression system for the production of recombinant protein in human 293S cells. Cytotechnology 15(1–3): 145–155. [DOI] [PubMed] [Google Scholar]
  20. Goldman MJ, Litzky LA, Engelhardt JF, Wilson JM. 1995. Transfer of the CFTR gene to the lung of nonhuman primates with E1‐deleted, E2a‐defective recombinant adenoviruses: A preclinical toxicology study. Hum Gene Ther 6(7): 839–851. [DOI] [PubMed] [Google Scholar]
  21. Gorziglia MI, Lapcevich C, Roy S, Kang Q, Kadan M, Wu V, Pechan P, Kaleko M. 1999. Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3. J Virol 73(7): 6048–6055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Gossen M, Bonin AL, Freundlich S, Bujard H. 1994. Inducible gene expression systems for higher eukaryotic cells. Curr Opin Biotechnol 5(5): 516–520. [DOI] [PubMed] [Google Scholar]
  23. Havenga MJ, Lemckert AA, Grimbergen JM, Vogels R, Huisman LG, Valerio D, Bout A, Quax PH. 2001. Improved adenovirus vectors for infection of cardiovascular tissues. J Virol 75(7): 3335–3342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Imler JL, Bout A, Dreyer D, Dieterlé A, Schultz H, Valerio D, Mehtali M, Pavirani A. 1995. Trans‐complementation of E1‐deleted adenovirus: A new vector to reduce the possibility of co dissemination of wild‐type and recombinant adenoviruses. Hum Gene Ther 6(6): 711–721. [DOI] [PubMed] [Google Scholar]
  25. Jackson RJ, Howell MT, Kaminski A. 1990. The novel mechanism of initiation of picornavirus RNA translation. Trends Biochem Sci 15(12): 477–483. [DOI] [PubMed] [Google Scholar]
  26. James E, Lee JM. 2001. The production of foreign proteins from genetically modified plant cells. Adv Biochem Eng Biotechnol 72: 127–156. [DOI] [PubMed] [Google Scholar]
  27. Jenkins N, Buckberry L, Marc A, Monaco L. 1998. Genetic engineering of alpha 2,6‐sialyltransferase in recombinant CHO cells. Biochem Soc Trans 26(2): S115. [DOI] [PubMed] [Google Scholar]
  28. Jønson L, Johnsen AH. 2001. Post‐translational modifications of heterologously expressed cholecystokinin in Saccharomyces cerevisiae . Scand J Clin Lab Invest Suppl 234: 87–92. [PubMed] [Google Scholar]
  29. Kawashima Y, Ogawa T, Kato M, Nakazato A, Tsuchida K, Hatayama K, Hirono S, Moriguchi I. 1993. Structure‐activity study of antihypertensive 1,4‐dihydropyridine derivatives having nitrooxyalkyl moieties at the 3 and 5 positions. Chem Pharm Bull (Tokyo) 41(6): 1060–1065. [DOI] [PubMed] [Google Scholar]
  30. Klessig DF, Brough DE, Cleghon V. 1984. Introduction, stable integration, and controlled expression of a chimeric adenovirus gene whose product is toxic to the recipient human cell. Mol Cell Biol 4(7): 1354–1362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Konishi J, Ishii Y, Onaka T, Maruhashi K. 2002. Purification and characterization of the monooxygenase catalyzing sulfur‐atom specific oxidation of dibenzothiophene and benzothiophene from the thermophilic bacterium Paenibacillus sp. strain A11‐2. Appl Microbiol Biotechnol 60(1–2): 128–133. Epub 2002 August 24. [DOI] [PubMed] [Google Scholar]
  32. Kruijer W, Schaik FM van, Sussenbach JS. 1981. Structure and organization of the gene coding for the DNA binding protein of adenovirus type 5. Nucleic Acid Res 9(18): 4439–4457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Ladisch S, Lovejoy FH, Hierholzer JC, Oxman MN, Strieder D, Vawter GF, Finer N, Moore M. 1979. Extrapulmonary manifestations of adenovirus type 7 pneumonia simulating Reye syndrome and the possible role of an adenovirus toxin. J Pediatr 95(3): 348–355. [DOI] [PubMed] [Google Scholar]
  34. Lamarche N, Massie B, Richer M, Paradis H, Langelier Y. 1990. High level expression in 293 cells of the herpes simplex virus type 2 ribonucleotide reductase subunit 2 using an adenovirus vector. J Gen Virol 71(Pt 8): 1785–1792. [DOI] [PubMed] [Google Scholar]
  35. Lawrence SM, Huddleston KA, Tomiya N, Nguyen N, Lee YC, Vann WF, Coleman TA, Betenbaugh MJ. 2001. Cloning and expression of human sialic acid pathway genes to generate CMP‐sialic acids in insect cells. Glycoconj J 18(3): 205–213. [DOI] [PubMed] [Google Scholar]
  36. Lazaris A, Arcidiacono S, Huang Y, Zhou JF, Duguay F, Chretien N, Welsh EA, Soares JW, Karatzas CN. 2002. Spider silk fibers spun from soluble recombinant silk produced in mammalian cells. Science 295(5554): 472–476. [DOI] [PubMed] [Google Scholar]
  37. Lee FS, Vallee BL. 1989. Expression of human placental ribonuclease inhibitor in Escherichia coli. Biochem Biophys Res Commun 160(1): 115–120. [DOI] [PubMed] [Google Scholar]
  38. Levy R, Weiss R, Chen G, Iverson BL, Georgiou G. 2001. Production of correctly folded Fab antibody fragment in the cytoplasm of Escherichia coli trxB gor mutants via the coexpression of molecular chaperones. Protein Expr Purif 23(2): 338–347. [DOI] [PubMed] [Google Scholar]
  39. Lochmüller H, Jani A, Huard J, Prescott S, Simoneau M, Massie B, Karpati G, Acsadi G. 1994. Emergence of early region 1‐containing replication‐competent adenovirus in stocks of replication‐defective adenovirus recombinants (delta E1 + delta E3) during multiple passages in 293 cells. Hum Gene Ther 5(12): 1485–1491. [DOI] [PubMed] [Google Scholar]
  40. Lusky M, Christ M, Rittner K, Dieterle A, Dreyer D, Mourot B, Schultz H, Stoeckel F, Pavirani A, Mehtali M. 1998. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J Virol 72(3): 2022–2032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Maizel JV, White DO, Scharff MD. 1968. The polypeptides of adenovirus. I Evidence for multiple protein components in viron and a comparison of types 2,7A and 12. Virology 36: 115–125. [DOI] [PubMed] [Google Scholar]
  42. Marchal I, Jarvis DL, Cacan R, Verbert A. 2001. Glycoproteins from insect cells: Sialylated or not? Biol Chem 382(2): 151–159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Massaer M, Mazzu P, Haumont M, Magi M, Daminet V, Bollen A, Jacquet A. 2001. High‐level expression in mammalian cells of recombinant house dust mite allergen ProDer p 1 with optimized codon usage. Int Arch Allergy Immunol 125(1): 32–43. [DOI] [PubMed] [Google Scholar]
  44. Massie B, Dionne J, Lamarche N, Fleurent J, Langelier Y. 1995. Improved adenovirus vector provides herpes simplex virus ribonucleotide reductase R1 and R2 subunits very efficiently. Biotechnology (NY) 13(6): 602–608. [DOI] [PubMed] [Google Scholar]
  45. Massie B, Couture F, Lamoureux L, Mosser DD, Guilbault C, Jolicoeur P, Bélanger F, Langelier Y. 1998. Inducible overexpression of a toxic protein by an adenovirus vector with a tetracycline‐regulatable expression cassette. J Virol 72(3): 2289–2296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Mattes R. 2001. The production of improved tissue‐type plasminogen activator in Escherichia coli . Semin Thromb Hemost 27(4): 325–336. [DOI] [PubMed] [Google Scholar]
  47. McQuillan DJ, Seo NS, Hocking AM, McQuillan CI. 2001. Recombinant expression of proteoglycans in mammalian cells. Utility and advantages of the vaccinia virus/T7 bacteriophage hybrid expression system. Methods Mol Biol 171: 201–219. [DOI] [PubMed] [Google Scholar]
  48. Menassa R, Zhu H, Karatzas CN, Lazaris A, Richman A, Brandle J. 2004. Spider dragline silk proteins in transgenic tobacco leaves: Accumulation and field production. Plant Biotechnol J 2(5): 431–438. [DOI] [PubMed] [Google Scholar]
  49. Meulen J ter, Bakker AB, Brink EN van den, Weverling GJ, Martina BE, Haagmans BL, Kuiken T, Kruif J de, Preiser W, Spaan W, Gelderblom HR, Goudsmit J, Osterhaus AD. 2004. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 363 (9427): 2139–2141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Mosser DD, Massie B. 1994. Genetically engineering mammalian cell lines for increased viability and productivity. Biotechnol Adv 12(2): 253–277. [DOI] [PubMed] [Google Scholar]
  51. O'Neal WK, Zhou H, Morral N, Aguilar‐Cordova E, Pestaner J, Langston C, Mull B, Wang Y, Beaudet AL, Lee B. 1998. Toxicological comparison of E2a‐deleted and first‐generation adenoviral vectors expressing alpha 1‐antitrypsin after systemic delivery. Hum Gene Ther 9(11): 1587–1598. [DOI] [PubMed] [Google Scholar]
  52. Reich NC, Sarnow P, Duprey E, Levine AJ. 1983. Monoclonal antibodies which recognize native and denatured forms of the adenovirus DNA‐binding protein. Virology 128(2): 480–484. [DOI] [PubMed] [Google Scholar]
  53. Rice SA, Klessig DF. 1985. Isolation and analysis of adenovirus type 5 mutants containing deletions in the gene encoding the DNA‐binding protein. J Virol 56(3): 767–778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Sarkar SN, Sen GC. 1998. Production, purification, and characterization of recombinant 2′,5′‐oligoadenylate synthetases. Methods 15(3): 233–242. [DOI] [PubMed] [Google Scholar]
  55. Sarkar S, Miwa N, Kominami H, Igarashi N, Hayashi S, Okada T, Jahangeer S, Nakamura S. 2001. Regulation of mammalian phospholipase D2:Interaction with and stimulation by G(M2) activator. Biochem J 359(Pt 3): 599–604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Seo NS, Hollister JR, Jarvis DL. 2001. Mammalian glycosyltransferase expression allows sialoglycoprotein production by baculovirus‐infected insect cells. Protein Expr Purif 22(2): 234–241. [DOI] [PubMed] [Google Scholar]
  57. Tait AS, Brown CJ, Galbraith DJ, Hines MJ, Hoare M, Birch JR, James DC. 2004. Transient production of recombinant proteins by Chinese hamster ovary cells using polyethyleneimine/DNA complexes in combination with microtubule disrupting anti‐mitotic agents. Biotechnol Bioeng 88(6): 707–721. [DOI] [PubMed] [Google Scholar]
  58. Tom RL, Caron AW, Massie B, Kamen AA. 1995. Scale‐up of recombinant virus and protein production in stirred‐tank reactors. Methods Mol Biol 39: 203–224. [DOI] [PubMed] [Google Scholar]
  59. van der Vliet P, Levine AJ, Ensinger MJ, Ginsberg HS. 1975. Thermolabile DNA Binding proteins from cells infected with a temperature‐sensitive mutant of adenovirus defective in viral DNA synthesis. J Virol 15(2): 348–354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Vliet P van der, Sussenbach JS. 1975. An Adenovirus type 5 gene function required for initiation of viral DNA replication. J Virol 67(2): 415–426. [DOI] [PubMed] [Google Scholar]
  61. Wu L, Berk AJ. 1996. Modification of adenovirus as gene transfer vector. Journal of Investigative Medicine 44(1): A190. [Google Scholar]
  62. Zhang WW, Koch PE, Roth JA. 1995. Detection of wild‐type contamination in a recombinant adenoviral preparation by PCR. Biotechniques 18(3): 444–447. [PubMed] [Google Scholar]

Articles from Biotechnology and Bioengineering are provided here courtesy of Wiley

RESOURCES